VJHemOnc Podcast

Myeloma 2017 day 1 highlights: immunotherapy advances, a new MM subtype and liquid biopsies

Nov 16, 2017

Doctors Keith Stewart, Leif Bergsagel, and Gareth Morgan discuss the highlights of Myeloma 2017 meeting, including immunotherapy advances, a new MM subtype, and the use of liquid biopsies. They explore advancements in CAR-T cell therapy and combination immunotherapies, the potential for double hit myeloma, and the importance of molecular diagnostics. The podcast also touches on amyloidosis updates and advancements in multiple myeloma diagnosis and imaging.

10:28

Creator website

Episode guests

Gareth Morgan

Keith Stewart

Leif Bergsagel

AI Summary

AI Chapters

Episode notes

Podcast summary created with Snipd AI

Quick takeaways

Exciting advances in CAR-T therapy for multiple myeloma show potential in manipulating the immune system to target malignant cells.

The use of liquid biopsies and genomics in multiple myeloma offers a comprehensive understanding of the disease and the potential for personalized treatment approaches.

Deep dives

Advances in CAR-T Therapy

The podcast discusses the exciting progress in CAR-T therapy for multiple myeloma. Researchers highlight the potential of CAR-T treatment in manipulating the immune system and using bi-specific antibodies to target malignant cells. They express optimism about the clinical effectiveness of CAR-T therapy, which may bring significant benefits to patients. The discussion also touches upon the importance of identifying the right target and delivery system, considering factors like cost and practicality.

Introduction

3min

Advancements in CAR-T Cell Therapy and Immunotherapies for Myeloma

2min

Advancements in Car T Cells, Double Hit Myeloma, and Liquid Biopsies

3min

Advances in Multiple Myeloma Diagnosis, Imaging, and Immunotherapies

3min

Fantastic advances in immunotherapy, including CAR T-cells, bispecific antibodies and potential immunotherapy combinations, were presented at the Myeloma 2017 meeting in Edinburgh, UK. In this panel discussion, Keith Stewart, MB, ChB and Leif Bergsagel, MD from the Mayo Clinic, Scottsdale, AZ and Gareth Morgan, MD, FRCP, FRCPath, PhD of UAMS Myeloma Institute, Little Rock, AR discuss the highlights from day 1 of the meeting. In addition to immunotherapy updates, the potential for a similar phenomenon to double hit lymphoma occurring in multiple myeloma (MM), which would identify a distinct MM subgroup in need of different therapies, is discussed. Furthermore, the application of liquid biopsies and molecular diagnostics in the clinic to improve the management of patients with MM is deliberated. Exciting amyloidosis updates are also touched upon.

The post Myeloma 2017 day 1 highlights: immunotherapy advances, a new MM subtype and liquid biopsies appeared first on VJHemOnc.